Why this ASX All Ords healthcare share is defying the market weakness and zooming higher

Australian Clinical Labs has made a bold takeover approach for its larger rival.

| More on:
A telehealth doctor at her desk.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Australian Clinical Labs has made a takeover offer for Healius 
  • It is a fellow healthcare company that is twice its size
  • Australian Clinical Labs believes the value will be unlocked from merging their operations

The Australian Clinical Labs Ltd (ASX: ACL) share price is having a solid start to the week.

In morning trade, the ASX All Ords healthcare share is up 3% to $3.73.

Why is the ASX All Ords healthcare share rising?

The catalyst for this has been news that the company has launched a bold takeover approach for larger rival Healius Ltd (ASX: HLS).

According to the release, Australian Clinical Labs has made a nil-premium all-scrip off-market takeover offer of 0.74 shares for every Healius share.

While this may seem like an odd takeover proposal from the ASX All Ords healthcare share, there is method to its madness.

Australian Clinical Labs believes the real value of the proposal will come when the two companies merge.

It believes the merged entity would deliver pro forma earnings before interest and tax (EBIT) of $361 million in FY 2023. This includes cost synergies and operational improvement benefits.

Based on its forecast earnings and belief that it could trade at the current blended forward EV/EBIT multiple of 17.5x, it estimates that it could deliver a value uplift of approximately $2.1 billion. It notes that this equates to a 90% increase in the value per Healius share implied by the offer consideration.

Another positive is that Australian Clinical Labs believes the merged group would be a candidate for ASX 100 inclusion in time.

What's next?

As things stand, Healius has told its shareholders that it is looking at the offer. In the meantime, it has informed shareholders to take no action.

Management commented:

The Board of Healius advises shareholders to take no action in respect of ACL's takeover offer. The Board will evaluate the offer and ACL's bidder's statement and provide shareholders with a recommendation in due course.

Until then, there is no need for shareholders to take any action. Healius will keep its shareholders fully informed of any further developments.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »